Bruker (NASDAQ:BRKR) Stock Price Down 6.5% - Time to Sell?

Key Points

• Bruker shares fell 6.5% to about $59.71, with trading volume roughly 82% below the average. Despite the decline, analysts maintain a “Moderate Buy” consensus, though the average price target of $57.86 is below the current price.
• The company’s latest quarterly results were mixed: adjusted EPS of $0.49 exceeded estimates of $0.38, while revenue of $838.5 million missed forecasts of $853.6 million. Bruker reaffirmed fiscal 2026 EPS guidance of $2.10–$2.15.
• Bruker declared a quarterly dividend of $0.05 per share, equal to a 0.3% annualized yield. Institutional investors own approximately 79.5% of the stock, while an executive recently sold 2,000 shares.

Bruker Corporation (NASDAQ:BRKR - Get Free Report)'s stock price fell 6.5% during trading on Tuesday. The company traded as low as $59.59 and last traded at $59.7050. Approximately 430,729 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 2,351,235 shares. The stock had previously closed at $63.86.

Wall Street Analyst Weigh In

BRKR has been the subject of several recent analyst reports. Guggenheim raised their price objective on shares of Bruker from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday. Citigroup decreased their price target on Bruker from $60.00 to $53.00 and set a "hold" rating on the stock in a research report on Wednesday, August 5th. Barclays raised their price target on Bruker from $53.00 to $60.00 and gave the company an "overweight" rating in a report on Wednesday, June 24th. The Goldman Sachs Group raised Bruker from a "strong sell" rating to a "strong-buy" rating in a research note on Monday, September 21st. Finally, Zacks Research cut Bruker from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $57.86.

Bruker Stock Down 3.5%

The firm has a 50 day moving average price of $58.94 and a 200-day moving average price of $52.04. The firm has a market cap of $9.39 billion, a price-to-earnings ratio of -87.59, a price-to-earnings-growth ratio of 1.93 and a beta of 1.22. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same period last year, the company earned $0.32 earnings per share. The company's revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's payout ratio is -28.57%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company's stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.20% of the stock is owned by corporate insiders.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently made changes to their positions in BRKR. Pallas Capital Advisors LLC acquired a new position in Bruker in the second quarter valued at about $570,746,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Bruker in the 2nd quarter valued at about $169,899,000. Sculptor Capital LP raised its position in shares of Bruker by 9.0% in the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock valued at $118,112,000 after acquiring an additional 270,000 shares during the period. Franklin Resources Inc. raised its position in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock valued at $108,796,000 after acquiring an additional 1,756,460 shares during the period. Finally, Alyeska Investment Group L.P. boosted its stake in Bruker by 86.2% during the 2nd quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company's stock worth $84,864,000 after acquiring an additional 653,007 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company's portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.